Roche Pharmaceuticals Names New CEO as O'Day Leaves to Head Gilead -- Update

(Adds detail about departing CEO, Gilead confirmation)

 
 By Cristina Roca 
 

Roche Holding AG (ROG.EB) on Monday said it has appointed a new chief executive for its Roche Pharmaceuticals business to replace the current CEO, who is leaving the company to head Gilead Sciences Inc. (GILD).

The Swiss pharmaceuticals company said Monday that CEO Daniel O'Day will step down as of Dec. 31, and that it is appointing William Anderson to the post effective Jan. 1.

Separately on Monday, Gilead said in a press release that it has appointed Mr. O'Day as chief executive and chairman of its board effective March 1. The U.S. biopharmaceutical company named Gregg Alton interim CEO for the period between Jan. 1 and Mr. O'Day's start date.

Roche said Mr. Anderson will also join its corporate executive committee.

Mr. Anderson is currently chief executive of Genentech, a Roche subsidiary company. He has worked for Roche since 2006.

Separately, Roche said it was proposing Hans Clevers for election to its board of directors. Mr. Clevers is a professor of molecular genetics at University Medical Center Utrecht, the company said.

Write to Cristina Roca at [e-mail]; @_cristinaroca

(END) Dow Jones Newswires

December 10, 2018 02:55 ET (07:55 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.